Loading stock data…
ASMB
$27.37+0.42 (+1.56%)
Market ClosedLast close May 1
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Assembly Biosciences, Inc. in the Healthcare sector is trading at $27.37. The stock is currently 31% below its 52-week high of $39.71, remaining 2.7% below its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why ASMB maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$27.37
Potential Upside
5%
Whystock Fair Value$28.74
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$448.91M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.16
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.96%
Volume
Today's trading volume
69,913
Recent News
Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of +586.28% and +300.65%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Assembly Biosciences: Q4 Earnings Snapshot
ASMB) on Thursday reported fourth-quarter net income of $22.1 million, after reporting a loss in the same period a year earlier. On a per-share basis, the South San Francisco, California-based company said it had profit of $2.48. The biotech drug developer posted revenue of $42.5 million in the period.
Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates
Metagenomi Therapeutics (MGX) delivered earnings and revenue surprises of -4.35% and -54.84%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates
Personalis (PSNL) delivered earnings and revenue surprises of +16.13% and -4.66%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +228.57% and +7.57%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?